DOI: https://doi.org/10.22141/2308-2097.52.3.2018.141843

Features of metabolic changes treatment at type 2 diabetes mellitus, obesity and arterial hypertension in patients with osteoarthritis taking into account indicators of genotypes of gene of anti-inflammatory interleukin-10 (IL-10, C592A)

J.I. Serdulets

Abstract


Background. A number of studies demonstrate the involvement of chronic systemic inflammation to the pathogenesis and progression of metabolic syndrome (type 2 diabetes mellitus with obesity and arterial hypertension) in patients with osteoarthritis. Its exacerbation associated with polymorbidity leads to a violation of the microcirculation, structure of collagen and promotes the degenerative process in the articular tissues, where the protein of the extracellular matrix matrilin-3 plays a role. It is proved to be associated with the level of the corresponding genotypes of pro-inflammatory and anti-inflammatory genes. The purpose of the study was to study changes in the genotypes of genes of anti-inflammatory interleukin-10 (IL-10, C592A) provoked by the treatment in patients with osteoarthritis combined with type 2 diabetes mellitus, obesity, arterial hypertension. Materials and methods. One hundred and sixteen patients with type 2 diabetes mellitus, obesity and arterial hypertension aged 16 to 65 years (mean age 40.5 years) were examined. To analyze the effectiveness of treatment depending on the genotype of the anti-inflammatory interleukin-10 (IL-10, C592A) the surveyed patients were divided into groups depending on those genotypes. Results. Due to the treatment, lipid peroxidation activity significantly decreased (more effective in carriers of the C-allele of the IL-10 gene (C592A)) against the background of not significant increase in antioxidant protection, which did not correlate with polymorphous variants of the IL-10 gene (rs1800872). The concentration of pro-inflammatory cytokine IL-18 reduced by 25.6 % in the CC-genotype carriers, in CA-genotype carriers — by 18.58 %, in AA-genotype patients — by 15.37 % (p > 0.05). And the level of anti-inflammatory IL-10, on the contrary, increased by 11.69, 18.0 and 23.08 %, respectively (p > 0.05). A slight increase in the extracellular matrix protein matrilin-3 was established in the CC-genotype carriers by 4.4 %, in the CA-genotype patients — by 13.5 %, and in the carriers of AA-genotype of the gene of IL-10 (C592A) — by 13.8 % (p > 0.05). Conclusions. The results of the treatment demonstrated a decrease in the activity of the lipid peroxidation (more effective in carriers of the C-allele of the IL-10 gene (C592A)) against the background of not significant increase in antioxidant protection, which did not correlate with polymorphous variants of the IL-10 gene (rs1800872). The therapy resulted in great reduction of the concentration of pro-inflammatory cytokine IL-18 in CC-genotype and CA-genotype patients, and increase in the level of anti-inflammatory IL-10 in carriers of the AA-genotype of the gene IL-10 (C592A). These patients experienced the improvement in matrilin-3 indices. The following study will be related to the effect of this treatment algorithm on proteolytic and collagenolytic activity in patients with metabolic syndrome and osteoarthrosis.


Keywords


diabetes mellitus; obesity; arterial hypertension; genotypes of interleukin 10 genes (IL-10, C592A); atorvastatin; L-arginine

References


Marengoni A, Angleman A, Fradiglioni L. Prevalence of disability according to multimorbidity and disease clustering: a population based-study. J Comorb. 2011 Dec 27;1:11-18. eCollection 2011.

Zhuravlova LV, Oliinyk MO. Disease-modifying treatment of osteoarthritis in patients with concomitant diabetes mellitus type 2. Bukovinian Medical Herald. 2015;19(4):66-70. (in Ukrainian).

Tanas OV, Khukhlina OS. Dynamic Parameters and Cytokine Oxidative Homeostasis during Diatsereyin Treatment in Patients with Osteoarthritis and Comorbid Diseases. Bulletin of problems biology and medicine. 2014;(111):241-244. (in Ukrainian).

Kovalenko VM. Comorbidity and ways of rational pharmacotherapy in rheumatology. Ukraïnsʹkij revmatologicnij zurnal. 2014;(56):12-13. (in Ukrainian).

Otte A, Maier-Lenz H, Dierckx RA. Good clinical practice: historical background and key aspects. Nucl Med Commun. 2005 Jul;26(7):563-74.

Schoukens P. The right to access health care: health care according to European social security law instruments. Med Law. 2008 Sep;27(3):501-33.

Abbing H.D. Developments in international/European health law. Eur J Health Law. 2009 Mar;16(1):81-8.

Vladymyrov YuA. Peroxide oxidation of lipids in the biological membrane. Terapevticheskiy arkhiv. 1999;(6):62-65. (in Russian).

Meshchyshen YF. Oxidation and reduction in the body of rats upon administration of ethonia. Ukrainian Biochemical Journal. 1983;(4):571-573. (in Russian).

Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul;31(7):1281-357. doi: 10.1097/01.hjh.0000431740.32696.cc.

Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315-2381. doi: 10.1093/eurheartj/ehw106.

Ministry of Нealth of Ukraine. Order № 564 dated June 13, 2016. On the approval and implementation of medical and technological documents on the standardization of medical care in the prevention of cardiovascular diseases. Available from: http://old.moz.gov.ua/ua/portal/dn_20160613_0564.html. (in Ukrainian).

Minafra L, Bravatà V, Saporito M, et al. Genetic, clinical and radiographic signs in knee osteoarthritis susceptibility. Arthritis Res Ther. 2014 Apr 9;16(2):R91. doi: 10.1186/ar4535.

Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H, et al. Association Between IL-10 Gene Promoter Polymorphisms (-592 A/C, -819 T/C, -1082 A/G) and Susceptibility to HBV Infection in an Iranian Population. Hepat Mon. 2016 Feb 20;16(2):e32427. doi: 10.5812/hepatmon.32427.

Korzh IV. Atorvastatin in the Treatment of Patients with Osteoarthritis Combined with Hypertension and Obesity. Bulletin of problems biology and medicine. 2013;(101):123-127.(in Ukrainian).




Copyright (c) 2018 GASTROENTEROLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта